RLAY

16.1201.32%
MM

Mark Murcko

Founder & Independent Director

Dr. Mark Murcko, Ph.D., serves as Board Member at Human Immunology Biosciences, Inc. Dr. Murcko is Chairman of Scientific & Technology Advisory Board of NuMedii, Inc.He has been Director at Dewpoint Therapeutics, Inc. since November 2018 and served as its Founding CSO until May 3, 2021. He is Member of Scientific Advisory Board at Dewpoint Therapeutics, Inc. He served as Chief Innovation Officer at Dewpoint Therapeutics, Inc. He serves as Member of Scientific Advisory Board and Board Member at Octant, Inc. since October 2021. He served as Member of Scientific Advisory Board of SQZ Biotechnologies Company until February 2021. He is a Co-Founder of Relay Therapeutics, Inc. and served as its Interim Chief Scientific Officer from February 2016 to December 2017. Dr. Murcko served as an Advisor and Consultant for Schrödinger since 2008. Dr. Murcko served as Senior Vice President of Strategy at Schrödinger, LLC. He has leadership experience in the biomedical field. He served as an Advisor at Nimbus Discovery, LLC. He served as the Chief Technology Officer and Vice President of Vertex Pharmaceuticals Incorporated until November 2011. He joined Vertex in 1990 as a Founding Scientist and served as its Senior Research Fellow. Dr. Murcko served as Chief Scientific Officer since November 2018 until May 3, 2021. He also worked at Merck Sharpe & Dohme, where he helped discover multiple clinical candidates against cardiovascular and ocular diseases, including inhibitors of the enzyme carbonic anhydrase for the treatment of glaucoma. He served as the Chairman of Scientific Advisory Board and Member of Scientific Advisory Board of Vertex Pharmaceuticals Incorporated until November 2011. He served as a Director of SQZ Biotechnologies Company and served as its Member of Scientific Advisory Board. He has been a Member of Scientific Advisory Board at Syros Pharmaceuticals, Inc since April 2013. He serves as a Member of Scientific Advisory Board at Ensemble Therapeutics Corporation and Schrödinger, LLC. He served as a Member of Scientific Advisory Board at Morphic Holding Inc. He served as Member of Scientific Advisory Board at Arvinas, Inc. He serves on the editorial boards of many scientific publications, including the Journal of Medicinal Chemistry and Drug Discovery Today. He is a Co-Inventor of Incivek™ (telaprevir), the world’s most widely prescribed HCV protease inhibitor, as well as Agenerase™ (amprenavir) and Lexiva™ (fosamprenavir), Vertex’s two marketed drugs for HIV. He is also a Co-Inventor of 8 other clinical candidates in the areas of cancer, inflammation/immunology and infectious disease and was responsible for starting many of Vertex’s programs in these and other disease areas. He has co-authored more than 85 scientific articles. Dr. Murcko has been Independent Director of Relay Therapeutics, Inc since July 2016. He is a Co-Inventor on more than 40 issued patents. He is the Northeastern Lecturer in the Department of Biological Engineering of Massachusetts Institute of Technology since July 2012. He is highly regarded as an Innovator in the pharmaceutical industry. He serves as Member of Scientific Advisory Board at Navitor Pharmaceuticals, Inc. He is a Key contributor to seven marketed drugs. Dr. Murcko received a Ph.D. in Organic Chemistry from Yale University in 1987 and a BS, summa cum laude in Chemistry and Applied Mathematics from Fairfield University in 1982. He holds a BA in Chemistry from the University of Minnesota.

Positions